Carnitine and type 2 diabetes

Diabetes/Metabolism Research and Reviews

Volumn 25, Issue SUPPL. 1, 2009, Pages

  Mynatt, Randall L ^a  

^a PENNINGTON BIOMEDICAL RESEARCH CENTER   (United States)

Author keywords

Acetyl CoA; Carnitine; Diabetes; Insulin resistance

Indexed keywords

ACETYLCARNITINE; CARNITINE; CARNITINE PALMITOYLTRANSFERASE; INSULIN;

CALORIMETRY; CONFERENCE PAPER; DRUG ACTIVITY; DRUG COST; DRUG EFFICACY; EXERCISE; FATTY ACID OXIDATION; FOOD INTAKE; GENE OVEREXPRESSION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLUCOSE OXIDATION; GLUCOSE UTILIZATION; GLYCEMIC CONTROL; GLYCOGEN ANALYSIS; HUMAN; HYPERINSULINEMIA; INSULIN RELEASE; INSULIN RESISTANCE; INTRAVENOUS GLUCOSE TOLERANCE TEST; METABOLOMICS; MITOCHONDRION; MUSCLE BIOPSY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; SIGNAL TRANSDUCTION;

ACYL COENZYME A; ANIMALS; CARNITINE; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 2; DIABETIC DIET; DIETARY SUPPLEMENTS; FATTY ACIDS; GLUCOSE CLAMP TECHNIQUE; HUMANS; INSULIN RESISTANCE; LIPIDS; MICE; MODELS, BIOLOGICAL;

EID: 73349102478     PISSN: 15207552     EISSN: 15207560     Source Type: Journal    
DOI: 10.1002/dmrr.987     Document Type: Conference Paper

References (30)

1. Boden G, Shulman GI. Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. Eur J Clin Invest 2002; 32(Suppl 3): 14-23.
2. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51: 7-18.
3. Shulman GI. Cellular mechanisms of insulin resistance. J Clin Invest 2000; 106: 171-176.
4. Unger RH. Lipotoxic diseases. Annu Rev Med 2002; 53: 319-336.
5. Kelley DE, Mandarino LJ. Fuel selection in human skeletal muscle in insulin resistance: a reexamination. Diabetes 2000; 49: 677-683.
6. De Fea K, Roth RA. Protein kinase C modulation of insulin receptor substrate-1 tyrosine phosphorylation requires serine 612. Biochemistry 1997; 36: 12939-12947.
7. Ravichandran LV, Esposito DL, Chen J, Quon MJ. Protein kinase C-zeta phosphorylates insulin receptor substrate-1 and impairs its ability to activate phosphatidylinositol 3-kinase in response to insulin. J Biol Chem 2001; 276: 3543-3549.
8. Chavez JA, Knotts TA, Wang LP, Li G, Dobrowsky RT. A role for ceramide, but not diacylglycerol, in the antagonism of insulin signal transduction by saturated fatty acids. J Biol Chem 2003; 278: 10297-10303.
9. Long SD, Pekala PH. Lipid mediators of insulin resistance: ceramide signalling down-regulates GLUT4 gene transcription in 3T3-L1 adipocytes. Biochem J 1996; 319: 179-184.
10. Holland WL, Brozinick JJ, Wang LP, Hawkins ED, Sargent KM, et al. Inhibition of ceramide synthesis ameliorates glucocorticoid-, saturated-fat-, and obesity-induced insulin resistance. Cell Metab 2007; 5: 167-179.
11. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 2008; 7: 45-56.
12. Muoio DM, Koves TR. Skeletal muscle adaptation to fatty acid depends on coordinated actions of the PPARs and PGC1 alpha: implications for metabolic disease. Appl Physiol Nutr Metab 2007; 32: 874-883.
13. Muoio DM, Koves TR. Lipid-induced metabolic dysfunction in skeletal muscle. Novartis Found Symp 2007; 286: 24-38; discussion 38-46, 162-3, 196-203.
14. Capaldo B, Napoli R, Di Bonito P, Albano G,Sacca L. Carnitine improves peripheral glucose disposal in non-insulin-dependent diabetic patients. Diabetes Res Clin Pract 1991; 14: 191-195.
15. De Gaetano A, Mingrone G, Castagneto M, Calvani M. Carnitine increases glucose disposal in humans. J Am Coll Nutr 1999; 18: 289-295.
16. Ferrannini E, Buzzigoli G, Bevilacqua S, Boni C, Del Chiaro D, Oleggini M, et al. Interaction of carnitine with insulin-stimulated glucose metabolism in humans. Am J Physiol 1988; 255: E946-E952.
17. Giancaterini A, De Gaetano A, Mingrone G, Gniuli D, Liverani E, Capristo E, et al. Acetyl-L-carnitine infusion increases glucose disposal in type 2 diabetic patients. Metabolism 2000; 49: 704-708.
18. Mingrone G, Greco AV, Capristo E, Benedetti G, Giancaterini A, De Gaetano A, et al. L-carnitine improves glucose disposal in type 2 diabetic patients. J Am Coll Nutr 1999; 18: 77-82.
19. Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol 2007; 581: 431-444.
20. Stephens FB, Constantin-Teodosiu D, Laithwaite D, Simpson EJ, Greenhaff PL. An acute increase in skeletal muscle carnitine content alters fuel metabolism in resting human skeletal muscle. J Clin Endocrinol Metab 2006; 91: 5013-5018.
21. Perdomo G, Commerford SR, Richard AM, Adams SH, Corkey BE, O'Doherty RM, et al. Increased beta-oxidation in muscle cells enhances insulin-stimulated glucose metabolism and protects against fatty acid-induced insulin resistance despite intramyocellular lipid accumulation. J Biol Chem 2004; 279: 27177-27186.
22. Sebastian D, Herrero L, Serra D, Asins G, Hegardt FG. CPT I overexpression protects L6E9 muscle cells from fatty acidinduced insulin resistance. Am J Physiol Endocrinol Metab 2007; 292: E677-E686.
23. Gonzalez-Ortiz M, Hernandez-Gonzalez SO, Hernandez-Salazar E, Martinez-Abundis E. Effect of oral L-carnitine administration on insulin sensitivity and lipid profile in type 2 diabetes mellitus patients. Ann Nutr Metab 2008; 52: 335-358.
24. Liang Y. The effects of oral L-carnitine treatment on blood lipid metabolism and the body fat content in the diabetic patient. Asia Pac J Clin Nutr 1998; 7: 192-195.
25. Derosa G, Cicero AF, Gaddi A , Mugellini A, Ciccarelli L, Fogari R, et al. The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003; 25: 1429-1439.
26. Rahbar AR, Shakerhosseini R, Saadat N, Taleban F, Pordal A, Gollestan B, et al. Effect of L-carnitine on plasma glycemic and lipidemic profile in patients with type II diabetes mellitus. Eur J Clin Nutr 2005; 59: 592-596.
27. Power RA, Hulver MW, Zhang JY, Dubois J, Marchand RM, Ilkayeva O, et al. Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia 2007; 50: 824-832.
28. Rhew TH, Sachan DS. Dose-dependent lipotropic effect of carnitine in chronic alcoholic rats. J Nutr 1986; 116: 2263-2269.
29. Sachan DS, Dodson WL. Effects of L-carnitine on carbon tetrachloride-induced changes in serum and liver lipids and acylcarnitines. J Environ Pathol Toxicol Oncol 1992; 11: 125-129.
30. Arduini A, Bonomini M, Savica V, Amato A, Zammit V. Carnitine in metabolic disease: potential for pharmacological intervention. Pharmacol Ther 2008; 120: 149-56.